Mr. Bisgaard joined Pivotal Life Sciences in 2017. He was previously Senior Partner at Novo Holdings/ Novo Ventures (US) Inc. As part of Novo’s senior team, he was responsible for Novo Ventures’ overall investment and portfolio strategy as well as the ongoing development of the Novo Ventures team in the US. Prior to that, Mr. Bisgaard was with Novo Ventures since 2001 in Denmark. He has investment and board experience from a large number of private and public US end European life sciences companies including e.g.: public companies Ra Pharma: RARX; Nevro: NVRO; Alder Biopharmaceuticals: ALDR; and current private companies e.g. Maplight, Engrial, and Addition. Prior to joining Novo Ventures, Peter was with McKinsey & Co. within the Scandinavian Corporate Finance and Strategy Group. He was part of the strategic and financial advisory teams in multiple large Private Equity and Corporate M&A transactions and strategy projects across industry sectors. Mr. Bisgaard obtained an M.Sc. in Engineering in 1998 from the Technical University of Denmark and was awarded a post-graduate degree in Mathematical Modelling in Economics by the European Consortium for Mathematics in the Industry.
